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ABSTRACT: In focused studies designed to follow up associations detected in a genome-wide association study (GWAS),
investigators can proceed to ﬁne-map a genomic region by targeted sequencing or dense genotyping of all variants in the region,
aiming to identify a functional sequence variant. For the analysis of a quantitative trait, we consider a Bayesian approach
to ﬁne-mapping study design that incorporates stratiﬁcation according to a promising GWAS tag SNP in the same region.
Improved cost-efﬁciency can be achieved when the ﬁne-mapping phase incorporates a two-stage design, with identiﬁcation of
a smaller set of more promising variants in a subsample taken in stage 1, followed by their evaluation in an independent stage
2 subsample. To avoid the potential negative impact of genetic model misspeciﬁcation on inference we incorporate genetic
model selection based on posterior probabilities for each competing model. Our simulation study shows that, compared to
simple random sampling that ignores genetic information from GWAS, tag-SNP-based stratiﬁed sample allocation methods
reduce the number of variants continuing to stage 2 and are more likely to promote the functional sequence variant into
conﬁrmation studies.
Genet Epidemiol 38:599–609, 2014. © 2014 Wiley Periodicals, Inc.
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Introduction
When large samples have been recruited for genome-wide
association study (GWAS) but whole genome sequencing is
stillnotaviableoptionforﬁne-mappingdespitethedecreas-
ing cost of next-generation sequencing (NGS) [Hedges et al.,
2011],targetedsequencingordensegenotypingofallvariants
in a candidate region is an attractive alternative [Almomani
et al., 2011]. For example, the Wellcome Trust Case Con-
trol Consortium (WTCCC) investigated regions identiﬁed
in GWASs for three diseases by dense genotyping of variants
acrosstheseregions,anddeﬁned,usingBayesfactors,credible
sets of variants that were likely to contain the causal disease-
associated variants [Wellcome Trust Case Control Consor-
tium et al., 2012]. Additional savings can be gained when the
ﬁne-mapping phase incorporates a two-stage design, analo-
gous to that previously developed in the GWAS setting [e.g.,
Skol et al., 2007; Thomas et al., 2009]. In stage 1, a subset of
theoriginalGWASsubjectsisselectedanddenselygenotyped,
examining all variants in the target region using expensive
regional sequencing technology. In stage 2, selected variants
identiﬁedinstage1aretypedintheremainingsubjectsusing
cost-effective genotyping technologies. Subsequently, asso-
ciation of these variants with the quantitative trait can be
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evaluated using the combined data from both stages. Fig-
ure1illustratesatwo-stageﬁne-mappingdesignbasedonan
existing GWAS sample.
The purpose of a ﬁne-mapping study for a complex quan-
titative trait is to identify a few variants, if not a single one,
that are potentially responsible for the variation in the trait,
estimategeneticeffectsizes,andcharacterizegeneticassocia-
tionatthegenelevel.TheinformationprovidedbyGWAStag
SNPscanbeusefulintheselectionofsubjectsforsequencing
[Chen et al., 2012; Schaid et al., 2013]. As opposed to a sim-
ple random-sampling (SRS) procedure, a good sample-size
allocation in a properly stratiﬁed sample (involving under-
or oversampling of strata) may improve efﬁciency of effect
size estimation at a functional sequence variant. One ap-
proach stratiﬁes the GWAS sample according to the three tag
SNP genotype categories: common homozygote, heterozy-
gote, and rare homozygote. For a quantitative trait, Chen
et al. [2012] found that estimation efﬁciency can be gained
when the frequency of sampling the homozygote strata is
higher than one would expect under SRS and also when the
frequency of samples from the heterozygote stratum is lower
than under SRS, provided that the additive genetic model
is correctly speciﬁed and the tag-seq linkage disequilibrium
(LD) is reasonably high, for example, above 0.80. In a case-
control setting, Schaid et al. [2013] showed that stratiﬁed
sampling based on both tag genotypes and case-control sta-
tus is not likely to have lower power than stratiﬁed sampling
C   2014 WILEY PERIODICALS, INC.Figure 1. Illustration of a two-phase two-stage design, with the GWAS phase examining 13 millions of tag SNPs in a total of N subjects and
the ﬁne-mapping phase focusing on m SNPs within a speciﬁed region identiﬁed by GWAS. The rows of the matrix correspond to N individuals
stratiﬁed by the GWAS tag SNP genotype (e.g., N = 5,000, with expected strata sizes of NAA = 2450, NAa = 2100, Naa = 450 for a tag SNP with
MAF=0.30),andthecolumnscorrespondtomsequencedSNPsorderedbychromosomeposition.Theﬁne-mappingphaseconsistsoftwo-stages:
in Stage 1, n1 individuals are sampled for sequencing of all variants in a region surrounding the tag SNP (e.g., n1 = 1,000, with random sampling of
an equal number of individuals from each of the three strata: nAA = 334, nAa = 333, naa, = 333 corresponding roughly to sampling fractions of 1/8, 1/4,
and 3/4, respectively). A subset of m2 promising sequence SNPs is identiﬁed (e.g., m2 equal to 30% of the m variants); the selected SNPs are not
necessarily contiguous, although their distribution within the region will depend strongly on the local LD structure. In Stage 2, the m2 variants are
genotyped in the N–n 1 remaining subjects.
based only on case-control status, and can sometimes have
substantially greater power. Both these studies considered
analysis under an additive or log-additive model for a func-
tional sequence variant, an assumption that may be violated
in practice.
Genetic model speciﬁcation in genetic analysis is a very
long-standing problem [for discussion see Joo et al., 2010;
Stephens and Balding, 2009; Strauch et al., 2003; Vukcevic
et al., 2011]. In our context, model misspeciﬁcation may
have a negative impact on the choice of variants for stage 2.
Although the additive model has been widely used in the
discovery stage for GWASs of many complex traits and dis-
eases, genetic effect size estimates at the sequence variant are
biased when the underlying genetic model is nonadditive.
For a nonfunctional sequence variant, the impact of model
misspeciﬁcation depends on LD with the functional variant.
Furthermore,thecorrectgeneticmodelforthesequencevari-
ant may be difﬁcult to identify when few heterozygotes at the
sequencevariantareobserved.Severalauthorshaveexplored
thenatureoftherelationshipbetweenaGWAStagSNP,used
to identify the region of interest, and a functional sequence
variant within the region, examining the impact of the LD
correlation on the association estimate, the ability to iden-
tify a genetic model, and the accuracy of localization [Faye
et al., 2013; Spencer et al., 2011; Vukcevic et al., 2011]. Char-
acterizing the genetic model, i.e., the mode of inheritance,
for a putative functional variant, even approximately, is of
substantial interest in this ﬁne-mapping process, and may be
informative for ongoing study design.
Inthisarticle,weconsideraBayesianapproachforregional
ﬁne-mappingwithselectionofacrediblesetofvariantssimi-
lar to that of Wellcome Trust Case Control Consortium et al.
[2012], but here we incorporate a two-stage sampling pro-
cedure in the ﬁne-mapping phase. The Bayesian approach
enables comparison among variants and the identiﬁcation
of a credible set that is analogous to, but more directly inter-
pretablethan,aconﬁdenceintervalinafrequentistapproach.
Bycomparisonsamonggeneticmodelsusingthestage1sam-
ple, as well as among variants, we aim primarily to improve
knowledgeaboutthepositionofthefunctionalsequencevari-
antandsecondarily,tolearnaboutthegeneticmodel.Selected
potentiallyfunctionalvariantsarethenevaluatedinstage2by
genotypingtheremainingsamplesusingamorecost-effective
technology. We focus on features associated with the stage 1
design and analysis, and the value of sampling and genetic
model information, including reduction in the size of the
credibleset, geneticmodel identiﬁcation, aswellastheprob-
ability of selecting a function sequence variant for stage 2.
The rest of this report is organized as follows. In the fol-
lowing section, we propose a Bayesian method for two-stage
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ants for conﬁrmation. To demonstrate how one can imple-
ment the proposed method in practice, we simulate data
from1000GenomesProjectandevaluatethreesamplealloca-
tionschemesundervarioussettings,includingcost-efﬁciency
considerations. We conclude with discussion.
Methods
Two-Stage Stratiﬁed Design
Consider a ﬁne-mapping study of a complex quantitative
traitdenotedbytherandomvariableY.LetGbethegenotype
of a tag SNP, with major and minor alleles A and a, that has
drawnattentiontoaregionpotentiallyharboringafunctional
sequencevariant.EachoftheindividualsintheGWASsample
will yield a pair of observed values (Gi,Yi), i = 1,...,N.W e
deﬁne three strata in the GWAS sample (Fig. 1) according to
the three categories of the tag SNP genotype, i.e., common
andrarehomozygoteandheterozygote,withinwhichwewill
select individuals into a stage 1 ﬁne-mapping sample. Let
n1 and n2 be the number of individuals in the stage 1 and
stage 2 samples, respectively, N = n1 + n2. Ideally, the stage 1
sample proportion n1/N should be chosen to maximize the
ability to correctly select the functional variant for typing in
stage 2, subject to ﬁnancial constraints on the genotyping
costs. Practically, the choice of n1is dictated by more modest
goals, e.g., ﬁnancial constraints and/or the ability to reduce
the scope of the ﬁne-mapping in stage 2 to a feasible number
of variants that includes the functional variant with high
probability. For individuals selected into the stage 1 sample,
we genotype all sequence variants found in the ﬁne mapping
region. Let YS1 and XS1 denote the response and sequence
genotype data in the stage 1 sample. We assume that among
all sequence variants examined in the ﬁne-mapping region
there is at least one functional sequence variant.
At stage 1 sampling, a good sample allocation is expected
tomaximizetheevidenceforthefunctionalsequencevariant
and minimize the number of variants selected for evaluation
in subsequent stages. In some cases, the region may contain
a large number of variants that are in high LD with the un-
known functional sequence variant such that they account
foralargeportionofthecredibleset(wecallthemhitchhiker
variants). We are interested in three representative sampling
schemes. The ﬁrst scheme uses SRS, which ignores informa-
tion from the tag SNPs (or imputed SNPs) provided in the
GWASphase.Thesecondschemesamplesanequalnumberof
individualsfromeachofthethreestratadeﬁnedbytheGWAS
tag genotypes (equal strata [ES]). The third uses a stratiﬁed
sampling strategy in which the relative number of samples
from the rare homozygote stratum is larger than would be
expected under SRS (HO). Similarly, the relative number of
samples from the heterozygote stratum is smaller than ex-
pected under an SRS scheme. The third sampling scheme is
expected to lead to better efﬁciency when the genetic model
for the functional variant is additive and the tag-seq LD cor-
relation is high, (e.g., r2 > 0.8). On the other hand, if the
genetic model is not additive and/or the tag-seq LD is low,
then increasing the relative frequency of samples from the
homozygous strata does not necessarily lead to improved
efﬁciency, because the sampling scheme becomes more like
SRS.
Model Formulation for a Quantitative Trait
We assume there is a functional sequence variant with a
minor allele frequency (MAF) of 1% or greater. Let X be
a variable that counts the number of copies of the minor
alleleatthisfunctionalvariantforanindividual.Withoutloss
of generality we consider a simple linear regression model,
but in practice a set of relevant nongenetic covariates can be
speciﬁedandincludedintheregressionmodels.Althoughthe
additive model is frequently used in GWAS for discovering
association at tag SNPs, the underlying genetic model for
a functional variant close to a promising tag SNP may not
be truly additive. Following Spencer et al. [2011], a general
three-parameter model is
Y = β0 + β1X + γ1X=1 + ε, (1)
which encompasses additive, dominant, and recessive mod-
els. Here β1 measures the increase or decrease in the value of
the trait with each additional copy of the minor allele, 1X=1
is an indicator function that takes value 1 for heterozygotes
and 0 for the two homozygotes, the dominance parameter γ
measures deviation from additivity, and ε follows a normal
distribution with mean 0 and variance σ2 independently
across individuals. Each of the genetic models can be re-
covered by setting the dominance parameter in (1) to a spe-
ciﬁc value: γ = 0 gives the additive model, and γ = β1 and
γ = –β1 correspond to the dominant and recessive mod-
els, respectively. Under additive, dominant, and recessive
models, the conditional mean E(Y|X) of the trait value is
β0 + β1X, β0 + β1(X + 1X=1), and β0 + β1(X – 1X=1), respec-
tively. As these three models involve the same number of
regression parameters, we focus on inference about the as-
sociation parameter β1, simplifying the model comparison
procedure described in the following subsections.
Bayesian Inference
Inthissection,weconsiderBayesianinferencewithastage1
sample of n1 subjects. Assume that a total of L variants in
the region are typed using targeted sequencing technology.
We analyze the stage 1 sample phenotype and sequence
genotype data (YS1,XS1) to narrow down the set of sequence
variants that are potentially functional, and to identify the
underlying genetic model. To develop the methods, we ﬁrst
specify priors for genetic models and regression parameters.
Then,forafunctionalsequencevariantwederivethemodel-
speciﬁc posterior for the regression parameters and compare
genetic models using Bayes factors. We specify selection of
the underlying genetic model for the sequence variant by
calculating the posterior probability for each of the three
genetic models. Finally, we analyze all sequence variants in
the region, and by making comparisons among variants,
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functional and select variants for the 95% credible set.
Prior Speciﬁcation
Let θ = (β,σ2)T be a vector of the parameters in the
quantitative trait model, where β = (β0,β 1)T are regres-
sion coefﬁcients. Let M1, M2,a n dM3 denote the addi-
tive, dominant, and recessive genetic models, respectively.
Let p(Mj) be the prior probability for Mj and p(θ|Mj)
be the prior distribution of θ under model Mj, j = 1,2,3.
In the absence of a priori information on the genetic
model, we assume that p(Mj) = 1/3a n dp(θ|Mj) = p(θ),
i.e., the prior for θ is independent of the underlying genetic
model. We specify a conjugate prior p(θ)gi v e nb yp(β,σ2) =
p(β|σ2)p(σ2), where p(β|σ2) = Normal(b0,σ2B0)a n d
p(σ2) = Inv – Gamma(ν0/2,σ2
0ν0/2), for some ν0 > 2. That
is, the prior joint density is normal-inverse-gamma
NIG(b0,B0,ν 0/2,σ2
0ν0/2). Here σ2
0 is a prior guess at the
variance and ν0 measures the strength of belief in that guess.
The matrix B0 is assumed diagonal. In cases of no strong a
priori belief concerning the magnitude of the genetic effect,
we specify the prior to be reasonably ﬂat over the range of
plausible effect values. Such vague prior distributions do not
favoranyparticularvalue,lettingtheposteriordependlargely
on the data alone.
Genetic Model Selection for a Sequence Variant
In this section we temporarily suppress the index for vari-
ants and present the model selection method for the func-
tionalvariant;butthesameanalysisisappliedtoeachvariant
in the region. The posterior for θ under genetic model Mj is
p

θ|YS1,XS1,Mj

= p

YS1|XS1,θ,Mj

p

θ|XS1,Mj

/cj,
where cj = p(YS1|XS1,Mj) = ∫p(YS1|XS1,θ,Mj)p(θ|XS1,
Mj)dθ is the normalizing constant of the posterior distribu-
tion. Theposterior meanandvarianceof θ areE(θ|YS1,XS1,
Mj) = ∫θp(θ|YS1,XS1,Mj)dθ and var(θ|YS1,XS1,Mj) =
∫{θ – E(θ|YS1,XS1,Mj)}{ θ – E(θ|YS1,XS1,Mj)}T p(θ|YS1,
XS1,Mj)dθ,r e s p e c t i v e l y .
The posterior distribution of θ can be derived analyti-
cally when the prior distribution is speciﬁed as normal-
inverse-gamma. This is desirable as it allows for fast pro-
cessing of the data and, because it does not rely on
Monte Carlo methods for analyzing the posterior dis-
tribution, it does not require additional computational
effort. For genetic model Mj,l e tXS1,j be the correspond-
ing design matrix. Deﬁne BS1,j = [B
–1
0 + {XS1,j}TXS1,j]
–1,
and βS1,j = BS1,j[B
–1
0 b0 + {XS1,j}TYS1]. Then the poste-
rior for θ is also a normal-inverse-gamma distribution
NIG(βS1,j,BS1,j,ν S1/2,σ2
S1,jνS1/2),whereνS1 = ν0 + n1 does
notdependonthegeneticmodel,andσ2
S1,j = [σ2
0ν0 + YT
S1YS1 +
bT
0B
–1
0 b0 – βT
S1,j{BS1,j}
–1βS1,j]/νS1. The posterior marginal
densities of β and σ2 as well as the marginal likelihood are
analytically tractable. Speciﬁcally, the posterior marginal for
βisamultivariatet-distributionwithνS1 degreesoffreedom.
ItcanbeshownthattheposteriormarginalmeanofβisβS1,j,
which is essentially a weighted average of the prior guess b0
and the maximum-likelihood (ML) estimate. The posterior
marginalvarianceofβisνS1/[{νS1 – 2}σ2
S1,jBS1,j].Theposte-
rior marginal for σ2 is inverse gamma with parameters νS1/2
and σ2
S1,jνS1/2.
We note that conditional on second-stage data, the
Bayesian analysis is independent of the sampling weights es-
tablished in stage 1. This follows because the stratifying vari-
able from the GWAS (tag SNP), although correlated with the
target sequence variant, is conditionally independent of the
response given the information on the functional sequence
variant. In online Supplementary Appendix A we outline a
proof that the inclusion probability and the distribution of
the sequence genotype do not enter into the calculation of
the posterior for θ.
Typically, Bayesian selection of a genetic model for a se-
quence variant involves computation of the posterior weight
of each model. Assuming all three sequence genotype cate-
gories are observed, we ﬁrst compare the three genetic mod-
els using the Bayes factor [e.g., Stephens and Balding, 2009;
Wakeﬁeld, 2009]. For instance, the Bayes factor comparing
Mj to Mj ,w i t hMj  being the reference genetic model, is
BFjj  = p

YS1|XS1,Mj

p

Mj

/

p

YS1|XS1,Mj  

p

Mj  

.
In the case of each model being equally likely a priori, i.e.,
p(Mj  ) = p(Mj), this is equivalent to computing the ratio of
the normalizing constants for the posteriors obtained un-
der Mjand Mj  . In general, 3 ≤ BFjj  ≤ 10 (or equivalently
1/10 ≤ BFj  j ≤ 1/3) suggests substantial evidence that the
data are in favor of genetic model Mj over Mj  ,w h e r e a s
BFjj  ≥ 10 (or equivalently BFj  j ≤ 1/10) suggests strong
evidenceinfavorofMj overMj  .Theconjugatepriorspeciﬁ-
cationmakesthecalculationofBayesfactorsstraightforward.
The posterior probabilities, or posterior weights, of ge-
netic modelsaredeﬁnedbywj = p(Mj|YS1,XS1),j = 1,2,3,
which summarize evidence for the underlying genetic mech-
anism at the seq variant after incorporating the observed
data and prior belief. These weights can be calculated as
wj = 1/{1 +

j   =j BFj  j}. The genetic model with the largest
posteriorweightisdeemedtobetheunderlyingmodel.Thisis
equivalent to selection based on normalizing constants such
that the best genetic model corresponds to the maximum
normalizing constant cmax = max{cj}3
j =1. For variants where
onlytw ogenotypecat egoriesar eobserv ed,w eassumeanad-
ditive genetic model and set cmax = c1. Using the Bayes factor
criteria, we would conclude that there is strong evidence that
the effect at the sequence variant follows genetic model Mj
whenever wj > 83.3% ,j = 1,2,3.
Selection of the 95% Credible Set
Havingﬁrstdeterminedageneticmodelforeachsequence
variant, we can compare any two variants in the region by
computing their associated Bayesian factor. But to compare
all sequence variants, we use the normalizing constant cor-
responding to the selected genetic model for each variant
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functional. Following the approach of Wellcome Trust Case
Control Consortium et al. [2012] for case-control genetic
studies, we deﬁne a credible set of variants that is 95% likely
to contain the functional variant for the quantitative trait,
using the posterior probabilities computed below. Our def-
inition of the credible set is similar to Wellcome Trust Case
Control Consortium et al. [2012] except that we allow for
differences in genetic models among the variants.
Assuming that the variant being examined is a functional
variant, we compute pk = P(variant k is functional|YS1,
{Xl
S1}L
l=1), the posterior weight of variant k being functional
given the quantitative trait and the genotype data of the L
variantsinthestage1sample,whereXl
S1 isthegenotypedata
ofvariantl.Speciﬁcally,theposteriorweightofvariantkbeing
functionalisgivenbypk = ck
max/
L
l=1 cl
max.Wesortthesepos-
terior weights in descending order p(1) ≥ p(2) ≥ ...≥ p(L).
Then, the 95% credible set is deﬁned such that the variants
in the set have posterior weights p(1),...,p(K),w h e r eK is
the minimum integer that satisﬁes
K
k=1 p(k) ≥ 0.95. With
a ﬁxed number of subjects in the stage 1 sample, a smaller
value of K implies that the sampling design performs better
in narrowing down the credible set that is likely to contain
the functional variant. In particular, a good design amounts
to (1) higher probability that the correct genetic model will
be identiﬁed for the functional seq variant, (2) higher prob-
ability that the functional seq variant will be selected into
the credible set, and (3) fewer seq variants assigned to the
credible set (i.e., smaller set size).
Evaluation of Stratiﬁed Sampling Designs
Design of Simulation Studies
TodemonstrateapplicationoftheBayesiantwo-stageﬁne-
mappingdesign,weconductedsimulationstudiesusingdata
derived from known population haplotypes. We evaluated
and compared two stratiﬁed sampling designs to a nonstrat-
iﬁed sampling strategy and examined the impact of various
factorsontheperformanceofthedesigns.Weconsideredthe
following factors: stage 1 sample size, MAFs of the tag SNP
and the functional sequence variant, tag-seq LD correlation,
and the noise-to-effect ratio (σ/β1).
Using the 1000 Genomes Project Phase 1 dataset of 381
European subjects, we simulated the genotypes of 201 com-
mon variants (MAF  0.05) within a 100 kb genomic region
surrounding the APOE gene, i.e., 45,400–45,500 kb on chro-
mosome 19, for a total of 5,000 subjects. The GWAS sample
size was selected in such a way that when the noise-to-effect
value was 4.9 and seq MAF = 0.2, the GWAS tag SNP geno-
type correlated with the functional sequence genotype in the
region would have identiﬁed association with the quantita-
tive trait that reached GWAS signiﬁcance using a frequentist
approach (see Supplementary Table S1 for required sample
sizes in other settings). We selected rs5117 to be the func-
tionalvariant,nottypedintheGWASphase,andrs75627662
tobethetagSNP,whichwastypedinGWASanddrewatten-
tiontotheregion.TheobservedMAFswere0.20and0.18for
rs5117andrs75627662,respectively.Thesetwovariantswere
selected to be the tag SNP and functional variant such that
the tag-seq LD correlation was r2 = 0.80 (r = 0.894), based
on the suggestion of Vukcevic et al. [2011] that the value of
r would be high when the tag SNP was identiﬁed in a GWAS
of the same sample, and larger than if the tag SNP had been
identiﬁedinapreviousindependentstudy.Inadditiontothe
tag rs75627662, another two nonfunctional common vari-
ants in the same region were found to be in high LD with the
functionalvariant.Thesetwo“hitchhiker”variants,rs483028
and rs438811, were in perfect LD with each other and had
a correlation r2 = 0.94 (r = 0.97) with the functional variant
(Fig. 2) and a correlation of r2 = 0.87 (r = 0.93) with the tag
SNP.
Figure 2. Common variants in the 100 kb region surrounding the
APOE gene (Source: 1000 Genomes Project Phase 1). In simulation C1,
rs75627662 (red diamond) and rs5117 (blue dot) were chosen to be the
tag and functional variants, respectively.
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(m = 332)
Simulation scenario Functional variant MAF GWAS tag SNP MAF
Tag-functional
correlation (r)
Number of
hitchhikers
(r > 0.8) Size (% of m) Size (m2)P (select) P (rank)
Common variant set (m = 201) with a single functional variant
C1 0.200 0.180 0.894 2 35% 70 0.95 0.35
Low-frequency and common variant set (m = 332) with a single functional variant
L1 0.022 0.142 0.372 6 65% 216 0.94 0.01
L2 0.046 0.055 0.880 9 58% 193 0.95 0.15
L3 0.087 0.099 0.936 5 58% 193 0.92 0.17
L4 0.142 0.120 0.905 3 45% 149 0.96 0.18
In scenarios C1 and L1–L4, each with a single functional variant, model parameters were speciﬁed by β0 = 5,β 1 = 0.25, and σ2 = 0.1, 0.5, 1.5. (See Supplementary Table S3 for
the speciﬁc SNP variant “rs numbers” in the APOE gene). The last four columns compare performance of the ﬁne-mapping method under selected values: n1 = 500,σ/β 1 = 4.9,
additive (ADD) genetic model, and equal strata sampling (ES). Size is the number m2 of sequence SNPs in the 95% credible set, expressed as a percentage of m or as a count.
P (select) is the probability that the functional variant is selected into the credible set. P (rank) is the probability that the functional variant is top-ranked in the credible set.
(A complete set of plots across a range of values is provided as Supplementary information).
We designed additional simulations to investigate the im-
pact of the functional variant MAF and the number of hitch-
hikers on the efﬁciency of each sampling design. Table 1 pro-
vides details on four additional simulation scenarios, L1–L4.
These scenarios feature low-frequency and common variant
sets (m = 332) and between three and nine hitchhikers. Sup-
plementary Table S3 speciﬁes the MAFs for the functional
SNP and the tag SNP for each scenario. For instance, in
simulation L1, the tag SNP is common (rs429358 with MAF
0.142)andthefunctionalvariantislowfrequency(rs1081105
with MAF 0.022). A total of six hitchhikers have correlation
with the functional variant greater than 0.8.
We generated quantitative trait data following (1) under
additive, dominant, and recessive genetic models. For each
genetic model, the regression coefﬁcients were speciﬁed by
β0 = 5, and β1 = 0.25, with three values of the normal resid-
ual variance σ2 = 0.1, 0.5, 1.5, corresponding to a noise-to-
effectratioof1.3,2.8,and4.9,respectively.Thisspeciﬁcation
of noise-to-effect ratio values covers a range of sampling de-
signefﬁciencies,andisequivalenttothespeciﬁcationofﬁxed
σ2 and varying β1. To investigate how the stage 1 sample size
inﬂuencestheperformanceofthedesign,wevariedthevalue
of n1 from 100 to 1000 with an increment of 100.
Threesampleallocationschemeswereconsidered:(1)SRS,
(2)equalsamplesizeforeachtaggenotypecategory(ES),and
(3) tag homozygote increased relative frequency (HO). For
the two tag-stratiﬁed sampling schemes, however, the rare
homozygote tag stratum may contain fewer subjects than
the allocated sample size when n1 is large. In such cases, we
ﬁrst sampled all subjects in the rare homozygote stratum.
Then, for the ES scheme we allocated the rest of the rare
homozygotesamplesizeequallytothecommonhomozygote
andheterozygotestrata,andfortheHOscheme,weallocated
the rest of the rare homozygote sample size to the common
homozygote only. An illustration of sample sizes allocated to
each stratum under the three sampling schemes is provided
by Supplementary Table S2 for a tag SNP MAF of 0.2.
Because diffuse priors are used when one has little prior
knowledge of the genetic association, we speciﬁed equal ge-
netic model prior probabilities, i.e., p(Mj) = 1/3, j = 1,2,3.
For the regression parameters, we chose a relatively ﬂat con-
jugate prior NIG(b0,B0,ν 0/2,σ2
0ν0/2), where the hyperpa-
rameters were speciﬁed by b0 = (0,0)T, B0 = diag(106,106),
σ2
0 = 0.5, and ν0 = 10.
Based on 1000 simulations, we evaluated the performance
of the three sample size allocation schemes according to the
characteristics of the credible set obtained in stage 1. Al-
though a complete two-stage study implementation would
typically incorporate joint analysis of stage 1 and stage 2
data, we did not include stage 2 data collection and joint
analysis as part of our simulation studies.
Simulation Study Results
Under the common variant scenario C1, when σ/β1 = 4.9
and the stage 1 sample size was small, e.g., n1 = 100, the per-
centage of variants selected into the credible set appeared to
be similar (at around 70% of 201) across all three sampling
schemes (Fig. 3A). The size of the credible set decreased as
n1 increased, particularly for ES and HO sampling schemes
whentheunderlying genetic modelwasadditive orrecessive,
with HO performing slightly better than ES. When n1 = 600,
forinstance,thepercentagesizeunderanadditivemodelwas
18% and 24% for HO and ES, respectively, but was 55% for
SRS. This suggests that informative tag-stratiﬁed sampling
can dramatically reduce the number of credible set variants,
which means reduced genotyping cost in stage 2. The three
samplingschemeshadsimilarperformanceforthedominant
genetic model. As expected, the size of the credible set de-
creased as the noise-to-signal ratio decreased for each given
stage 1 sample size and underlying genetic model (Supple-
mentary Figs. S1.1 and S1.2). With a stage 1 sample of size
n1 = 200 and a σ/β1 value of 1.3, for instance, ES and HO
schemes resulted in credible sets as small as 1% of the total
variants(2/201)intheregion.Similarﬁndingswereobtained
for the scenarios with the low-frequency variant set (< 5%)
and various LD structures (Table 1), with the ES scheme
nearly always performing better than SRS in reducing the
size of the credible set, and often better than HO (Fig. 3B,
Supplementary Figs. S2.2.1–3, S2.3.1–3, and S2.4.1–3).
604 Genetic Epidemiology, Vol. 38, No. 7, 599–609, 2014Figure 3. The size of the selected 95% credible variant set under three sampling schemes: simple random sampling (SRS), equal sample size for
each tag genotype category (ES), and tag homozygote oversampling (HO). From left to right: Data were simulated under additive, dominant, and
recessive genetic models, respectively. Results are based on 1000 simulations. (A) Upper panels are common variant scenario C1 (m = 201) with
σ/β1 =4 .9. (B) Lower panels are low-frequency variant scenario L1 (m = 332) with σ/β1 =2 .8.
When the stage 1 sample size was small, e.g., n1 = 100, the
probabilityofselectingthefunctionalvariantintothecredible
set under the SRS scheme was higher than that under ES and
HO(Fig.4A,seealsoSupplementaryFig.S2.2.6).Formodest
values of n1, SRS performed similarly to ES and HO under
additive and dominant models but underperformed under
a recessive model. When n1 = 1,000, the three schemes had
similar rates for successfully selecting the functional variant,
all close to 95% (Fig. 4A and B), likely because the variants
that had high correlation with the functional variant could
be well separated from those that had low correlation. As
the noise-to-signal ratio decreased, the rate was above 95%
in general and close to 100% for a large stage 1 sample size
(Supplementary Figs. S1.3 and S1.4).
For ranking the functional variant as the top variant, the
ES and HO schemes performed better than SRS under the
additive and recessive models for the common variant set
(Fig. 5A). However, the probability of ranking rs5117 as the
topvariantwasbelow5%forallthreeschemeswhenn1 = 100
and σ/β1 = 4.9, regardless of the underlying genetic model.
When n1 increased to 1,000 (of a GWAS sample of 5,000),
this probability increased to about 50% for ES and HO and
40%forSRSundertheadditivemodel,andincreasedto60%
for ES and HO and 20% for SRS under the recessive model.
The low probability here can be explained by the existence
of hitchhiker variants that compete with the functional vari-
ant [Faye et al., 2013]. The SRS and ES schemes performed
slightly better than HO under the dominant model, with the
probability of ranking rs5117 as the top being 75% for SRS
and ES and 60% for HO, for n1 = 100. As the noise-to-signal
ratio decreased, the probability increased for all sampling
schemes and all underlying genetic models (Supplementary
Figs. S1.5 and S1.6). For the low-frequency variant set, the
probability of the functional SNP being ranked ﬁrst depends
on the MAF of the functional variants, being very low for
MAF = 0.022 under all three models (Fig. 5B). However, for
higher MAF (scenarios L2–L4, Supplementary Figs. S2.2–
2.4),theseprobabilitiesweregenerallymoderatetohighwith
ES sampling often performing best.
Finally, to illustrate the value of genetic model selection
in the determination of the 95% credible set we conducted
an additional simulation that compared analyses with and
without genetic model selection. When one is not interested
in selecting the genetic model (without model selection), γ
is set to 0, –β1 or +β1 for additive, dominant, and recessive
models, respectively (according to (1)). Otherwise, when the
Genetic Epidemiology, Vol. 38, No. 7, 599–609, 2014 605Figure 4. Empirical probability of selecting the functional variant into the 95% credible set under three sampling schemes: simple random
sampling (SRS), equal sample size for each tag genotype category (ES), and tag homozygote oversampling (HO). From left to right: Data were
simulated under additive, dominant, and recessive genetic models, respectively. Results are based on 1000 simulations. (A) Upper panels are
common variant scenario C1 (m = 201) with σ/β1 =4 .9. (B) Lower panels are low-frequency variant scenario L1 (m = 332) with σ/β1 =2 .8.
genetic model is uncertain (with model selection), we com-
pute parameter estimates under the model most favored by
thedataintermsofitsposteriordistribution.Theparameters
were speciﬁed by β0 = 5a n dσ/β1 = 4.9, with a stage 1 sam-
ple size of n1 = 600. For all three sample allocation schemes,
including genetic model selection consistently reduced the
size of the credible set compared to analysis without model
selection, particularly for cases in which the additivity as-
sumption was incorrect (Table 2). When the true underlying
model was dominant and ES allocation was used, for exam-
ple,thepercentagesizeofthecrediblesetwas22.1%assuming
additivity but was only 11.2% with genetic model selection.
The results in Table 2 and the additional results for the sim-
ulations with low-frequency variants (Supplementary Figs.)
show that with model selection, ES often dominates HO in
terms of the probability of including the functional variant
in the credible set and in terms of the probability of ranking
the functional variant as ﬁrst. This may be explained largely
by the better ability of ES to identify the underlying genetic
model (Supplementary Figs. S1.7–1.9). The reduced size of
the credible set means reduced cost for typing the selected
variants in stage 2.
The two-stage approach proposed here reveals a subtle
trade-off between the costs involved in each of the two stages
of the analysis. Our simulations show that as we increase the
stage 1 sample size we reduce the size of the credible set and
thusreducethecostsinvolvedinthesecondstage.Inthenext
section we assess this trade-off from a cost-efﬁciency (CE)
perspective.
CE Considerations
Assuming the sequencing cost is $c1 per individual, ob-
tained by targeted sequencing for example, the stage 1 cost is
n1 ×c1.Instage2ofthetwo-stagedesign,customgenotyping
isconductedform2 markersatacostof$c2 perindividualper
marker, and the stage 2 cost is n2 (m2 × c2). The n2 individ-
uals are those not selected for sequencing in stage 1 (n2 = N–
n1). (Although in some circumstances, it may be desirable to
606 Genetic Epidemiology, Vol. 38, No. 7, 599–609, 2014Figure 5. Empirical probability of the functional variant being ranked as the top variant in the region under three sampling schemes: simple
random sampling (SRS), equal sample size for each tag genotype category (ES), and tag homozygote oversampling (HO). From left to right: Data
were simulatedunder additive, dominant, andrecessive genetic models, respectively. Resultsare based on1000simulations. (A)Upper panels are
common variant scenario C1 (m = 201) with σ/β1 =4 .9. (B) Lower panels are low-frequency variant scenario L1 (m = 332) with σ/β1 =2 .8.
genotype everyone, n2 = N, to conﬁrm the sequencing or to
create a reference panel.) For example, if N = 5000, n1 = 500,
c1 = $1000, n2 = 4500, m2 = 100, and c2 = $0.50, then the total
two-stage cost is $500,000 + $225,000 = $725,000 compared
to a one-stage cost of $5 million.
For ﬁxed values of c1 and c2, the stage 1 cost increases lin-
early in n1, whereas the stage 2 cost decreases monotonically
in n1, because the expected size of the credible set is nonin-
creasing in n1 (as seen in Fig. 3). However, the total cost can
be increasing or decreasing in n1, depending on the values of
(c1/c2) and the rate of decline in m2. In some cases, the total
cost can be minimized (see Supplementary Appendix B for
details).Asn1 increases,theprobabilitythatafunctionalvari-
ant falls within the 95% credible set also increases (as seen in
Fig. 4), which we loosely refer to as “power.” We deﬁne CE to
be Power divided by Cost, with higher values corresponding
tohigherpowerand/orlowercost.Otherdeﬁnitions,notably
theARCE ={(varianceoflnRR)/cost}ofThomasetal.[2013]
has the advantage that the numerator is not bounded above
by 1.0. Nevertheless, it is desirable to require high power in
stage 1, so that the functional variant is unlikely to be left out
of stage 2. The trends in CE are then determined largely by
trends in the total cost. In Figure 6, we calculate CE values
based on empirical estimates of the proportion of variants
retained in the credible set (m2/m) and the probability that
thefunctionalvariantisincludedtherein,whichweobtained
from the simulations for SRS and ES sampling under the ad-
ditive model (Figs. 3A and 4A). As might be expected, high
cost ratios, (c1/c2) > 2,000, favor smaller n1, and increasing
stage 2 costs reduce CE (Fig. 6). Except for the smallest stage
1 sample size (where SRS has higher power), CE is consis-
tently higher under the ES sample allocation, in accordance
with more efﬁcient reduction in the number of variants to
be genotyped in stage 2. Under ES, CE is maximized at n1 =
500and600,forc2 =1.0and2.0,respectively,whenc1 =1000
(Fig.6A),andatn1 =800whenc1 =100.Ourobservationthat
ES(andoftenHO)allocationsforlow-frequencyvariantsand
otherLDstructuresalsoreducetheproportion(m2/m)mor e
than SRS suggests that CE patterns will be similar in these
settings.
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withoutgeneticMSunderthecommonvariantsimulationscenario
C1 with the three sample allocation schemes: SRS, equal sam-
ple size for each tag genotype category (ES), and tag homozygote
oversampling (HO)
ADD DOM REC
Allocation scheme No MS MS No MS MS No MS MS
Size of the credible set (%)
SRS 55.5% 52.6% 13.0% 12.1% 83.2% 68.0%
ES 29.8% 25.8% 22.1% 11.2% 38.8% 21.8%
HO 19.3% 17.9% 12.5% 9.4% 27.0% 20.2%
P (functional variant being selected into the credible set)
SRS 0.984 0.965 0.972 0.980 0.952 0.956
ES 0.986 0.970 0.980 0.970 0.986 0.974
HO 0.964 0.952 0.958 0.963 0.964 0.974
P (functional variant being ranked #1)
SRS 0.238 0.198 0.542 0.554 0.034 0.102
ES 0.396 0.390 0.396 0.580 0.380 0.610
HO 0.392 0.376 0.306 0.448 0.404 0.563
Data were generated under each of additive (ADD), dominant (DOM), and recessive
(REC) models with n1 = 600,σ/β 1 = 4.9 in a simulation independent of that reported
in Figures 3 to 5. For cases without MS (no MS), the analysis assumed an additive
genetic model.
MS, model selection; SRS, simple random sampling.
Discussion
Two-stage designs for quantitative traits or complex dis-
eases that minimize cost and maximize power are of interest
as strategies to narrow down the set of variants associated
with the traits [Stanhope and Skol, 2012]. Using a Bayesian
approach we considered a two-phase two-stage design for
ﬁne-mapping a region detected by a GWAS of a quantita-
tive trait. The two-phase approach relies on high power in
the phase I GWAS tag SNP to correctly identify a region for
phase II ﬁne-mapping that includes at least one functional
SNP. Under the two-stage design, all variants in the region
are ﬁrst examined in a subset of subjects, using an expensive
sequencingtechnology,andpromisingpotentiallyfunctional
variants are selected into a 95% credible set. In stage 2 the
selected variants are then typed in the remaining subjects
usingarelativelycost-effectivegenotypingtechnology.Inthe
absence of knowledge of the genetic model for a candidate
functional variant, additive coding can lead to loss of efﬁ-
ciency when the additivity assumption is incorrect. In the
stage 1 analysis, we employed genetic model selection for
each candidate variant using the Bayes factor, and compared
allvariantswithintheregiontoselectacrediblesetforfurther
evaluation.
As opposed to random selection of individuals into the
stage 1 sample, our simulations show that a more informa-
tive sample can be obtained by stratiﬁed sample allocation,
suchassamplinganequalnumberfromeachtagSNPstratum
oraproportionatelylargernumberfromthehomozygotetag
SNP strata. A well-chosen sample size allocation scheme has
the potential to improve functional variant localization and
reducethesizeofthe95%crediblevariantsetforevaluationin
a subsequent stage. Various factors, including stage 1 sample
sizeandtag-seqcorrelationcaninﬂuencetheperformanceof
a two-stage ﬁne-mapping design. Our simulations conﬁrm
the intuition that the efﬁciency of the tag-stratiﬁed sampling
strategy increases with tag-seq correlation. When the true
genetic model is correctly identiﬁed, notably by Bayesian ge-
netic model selection, an informative sample size allocation
schemecaneffectivelyreducetheposteriorvarianceoftheas-
sociation parameter. Across the various scenarios evaluated
in the simulation studies, the ES sampling strategy gener-
ally performed equivalently or better than the HO sampling
strategy,particularlywithrespecttodecreasingthesizeofthe
credible set.
The number of variants that will be included in a credible
set is a random variable that depends mainly on the stage
Figure 6. Trends in cost efﬁciency (CE) deﬁned as Power/Cost with stage 1 sample size n1 increasing from 100 to 1,000 for the SRS (gray lines)
and ES (black lines) sample allocation schemes. The stage 2 sample size is n2 = N–n 1 with N = 5,000. A total of m sequence variants are identiﬁed
in stage 1, and a proportion q =( m2/m) are genotyped in stage 2. Empirical values for q and for power used to calculate CE as a function of n1 were
obtained from the common variant simulation study under an additive model. Cost depends on c1, the stage 1 per individual sequencing cost, and
on c2, the stage 2 per individual per marker genotyping cost. For a ﬁxed value of c1, CE decreases as c2 increases from 0.50 to 2.00.
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the sampling design. This differs from the two-stage GWAS
designconsideredbySkoletal.[2007],wheretheproportion
ofvariantstobe typedatstage2canbepre-speciﬁed.Ifthere
is more than one functional variant in the ﬁne-mapping
region, then the probability that a secondary functional vari-
ant is included in the credible set will depend on whether it
is tagged by the GWAS SNP used for stratiﬁcation, and on its
effectsizeandMAFrelativetotheprimaryfunctionalvariant.
We suggest that a ﬁne-mapping region be determined such
thatthereisadominanttagSNP.Withcompleteinformation
available on the credible set of variants, one can jointly ana-
lyze stage 1 and 2 data and update the posterior probabilities
of these variants being functional. Efﬁcient stage 1 sampling
and analysis for identifying a credible set of variants for
stage 2, however, remain crucial in a two-stage ﬁne-mapping
design.
In our Bayesian analysis we focused on common and low-
frequency variants for association with the trait. In practice,
a large portion of the variants discovered in a region will
be low-frequency (MAF between 0.01 and 0.05) and rare
(MAF < 0.01). For sufﬁciently large samples, single variant
analysis for credible set construction is feasible even for un-
common variants, but the incorporation of aggregated rare-
variant statistics into a two-stage design is likely to be of
interest, provided the pooled rare variants comprise a mean-
ingful unit of analysis. In circumstances where these aggre-
gation methods select a large number of rare variants into
the credible set, the reduction of genotyping costs in stage 2
may be too modest compared to performing dense genotyp-
ing/sequencing,underminingtheoriginalgoalofatwo-stage
ﬁne-mapping design.
Inadditiontotag-SNP-basedtwo-phasesamplingdesigns,
there are other approaches to design for sequencing studies.
Trait-dependent sampling designs, for example, have been
implemented for sequencing studies of quantitative traits, in
which subjects in the two extremes of the trait distribution
areselectedwiththehopethatminorallelesatthefunctional
variant are enriched in the selected sample [e.g., Lin et al.,
2013; Yilmaz and Bull, 2011]. Sequencing data, obtained on
theselectedsubjects,canbeanalyzedforassociationwiththe
quantitative trait either using methods that correctly adjust
for the sampling design, or simply using binary regression
modelsbytreatingtheselectedsubjectsascasesandcontrols.
Althoughtrait-dependentsamplingismoresuitableforWGS
studies in which multiple regions are examined, the work of
Schaidetal.[2013]suggestsitmaybeworthwhiletocombine
trait- and SNP-based sampling.
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